For example, the humanized anti-CD19 CAR did not show a difference in the ability to kill target cells in vitro and in mice compared to parental CAR, but it exhibited significantly lower side effects in the patients with B-cell lymphoma (Heard et al., 2021). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.